NASDAQ:HTBX - Heat Biologics Stock Price, News & Analysis

$0.57
+0.01 (+1.79 %)
(As of 08/16/2019 04:00 PM ET)
Today's Range
$0.53
Now: $0.57
$0.58
50-Day Range
$0.51
MA: $0.64
$0.78
52-Week Range
$0.51
Now: $0.57
$2.24
Volume43,100 shs
Average Volume404,602 shs
Market Capitalization$19.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.79 million
Book Value$0.93 per share

Profitability

Net Income$-15,730,000.00
Net Margins-319.80%

Miscellaneous

Employees30
Market Cap$19.42 million
Next Earnings Date8/20/2019 (Estimated)
OptionableNot Optionable

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.


Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Heat Biologics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

How were Heat Biologics' earnings last quarter?

Heat Biologics Inc (NASDAQ:HTBX) posted its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company earned $1.84 million during the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative return on equity of 68.17% and a negative net margin of 319.80%. View Heat Biologics' Earnings History.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release their next quarterly earnings announcement on Tuesday, August 20th 2019. View Earnings Estimates for Heat Biologics.

What price target have analysts set for HTBX?

3 brokerages have issued 1 year target prices for Heat Biologics' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Heat Biologics' stock price to reach $6.6667 in the next twelve months. This suggests a possible upside of 1,069.6% from the stock's current price. View Analyst Price Targets for Heat Biologics.

What is the consensus analysts' recommendation for Heat Biologics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

Has Heat Biologics been receiving favorable news coverage?

Headlines about HTBX stock have been trending negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heat Biologics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Heat Biologics.

Are investors shorting Heat Biologics?

Heat Biologics saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 366,600 shares, a drop of 40.9% from the June 30th total of 620,500 shares. Based on an average daily trading volume, of 363,400 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.2% of the company's shares are short sold. View Heat Biologics' Current Options Chain.

Who are some of Heat Biologics' key competitors?

What other stocks do shareholders of Heat Biologics own?

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the folowing people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
  • Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
  • Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor

Who are Heat Biologics' major shareholders?

Heat Biologics' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.90%). View Institutional Ownership Trends for Heat Biologics.

Which major investors are buying Heat Biologics stock?

HTBX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Heat Biologics.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $0.57.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $19.42 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.

What is Heat Biologics' official website?

The official website for Heat Biologics is http://www.heatbio.com/.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]


MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel